Standout Papers

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer 2016 2026 2019 2022 2.3k
  1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016)
    Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine
  2. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study (2016)
    Glenwood Goss, Chun‐Ming Tsai et al. The Lancet Oncology
  3. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer (2017)
    Suresh S. Ramalingam, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  4. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer (2020)
    Geoffrey R. Oxnard, J.C.-H. Yang et al. Annals of Oncology

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 56 standout
Sub-graph 1 of 22

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
2 intermediate papers

Works of Helen Mann being referenced

Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer
2017
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Helen Mann 4000 4433 356 1592 89 5.9k
Rogério Lilenbaum 5515 5344 464 2115 105 8.3k
Chee Khoon Lee 5043 4817 515 1739 169 7.2k
Joaquı́n Mateo 3171 3026 294 2046 145 5.7k
Lini Pandite 2723 3703 310 2913 75 5.9k
Antonio Marchetti 2678 2858 374 2524 110 5.7k
Janusz Rolski 2802 2724 352 753 44 4.1k
Hisayuki Shigematsu 4169 5189 427 2901 73 7.0k
P. Koralewski 4430 3406 907 2065 58 6.9k
Mircea Dediu 4697 5031 332 1570 54 6.5k
В. А. Горбунова 4426 5438 937 2215 59 7.0k

All Works

Loading papers...

Rankless by CCL
2026